PUBLISHER: The Business Research Company | PRODUCT CODE: 1889591
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889591
Stem cell therapy for infertility is an advanced regenerative treatment approach that uses stem cells to restore or enhance the function of reproductive tissues and organs in both males and females. It aims to repair damaged ovarian, testicular, or endometrial tissues, improve gamete quality, and support hormonal balance.
The primary components of stem cell therapy for infertility include male infertility treatment and female infertility treatment. Stem cell therapy for male infertility is a regenerative approach that uses stem cells to improve or restore sperm production and overall reproductive function in men experiencing reduced fertility. Treatment types include autologous stem cell therapy, allogeneic stem cell therapy, and combination therapy. Cell sources include embryonic stem cells, adult stem cells, and induced pluripotent stem cells. Applications include ovarian insufficiency, uterine infertility, and genetic disorders. Primary end users include hospitals, specialty clinics, and research institutes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The stem cell therapy for infertility market research report is one of a series of new reports from The Business Research Company that provides stem cell therapy for infertility market statistics, including stem cell therapy for infertility industry global market size, regional shares, competitors with a stem cell therapy for infertility market share, detailed stem cell therapy for infertility market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy for infertility industry. This stem cell therapy for infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The stem cell therapy for infertility market size has grown rapidly in recent years. It will grow from $1.60 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be linked to the increasing prevalence of infertility among both men and women, rising demand for assisted reproductive technologies, growing awareness of stem-cell-based fertility treatments, the expansion of specialized fertility clinics, and greater adoption of regenerative medicine approaches.
The stem cell therapy for infertility market size is expected to see rapid growth in the next few years. It will grow to $3.43 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be driven by growing government and private sector support for fertility treatments, rising clinical success rates of stem-cell-based therapies, expanding collaborations between biotech companies and fertility centers, increasing demand for non-invasive fertility treatment options, and a stronger focus on improving reproductive outcomes through stem cell applications. Major trends in the forecast period include advancements in induced pluripotent stem cells, progress in ovarian stem cell techniques, innovations in endometrial regeneration therapy, integration of artificial intelligence in fertility treatments, and the development of advanced biomaterial scaffolds for repairing reproductive tissues.
The rising cases of infertility are expected to significantly contribute to the growth of the stem cell therapy market for infertility in the coming years. Infertility is defined as the inability of a couple to conceive after 12 months or more of regular unprotected sexual intercourse. The increasing prevalence of infertility is mainly due to delayed childbearing, as many individuals opt to have children later in life, leading to reduced fertility because of the natural decline in reproductive potential with age, particularly among women. Stem cell therapy for infertility offers promising solutions by regenerating damaged reproductive tissues, enhancing ovarian and testicular function, and improving the chances of conception. For instance, in April 2023, a report from the World Health Organization (WHO) indicated that infertility affects approximately 17.5% of the global adult population, or about 1 in 6 people, emphasizing the growing need to expand access to affordable, high-quality fertility care. Therefore, the increasing infertility cases are expected to drive the expansion of the stem cell therapy for infertility market.
Leading companies in the stem cell therapy for infertility market are focusing on advancements in stem cell technologies, such as induced pluripotent stem cells (iPSCs), to improve personalized regenerative treatments, enhance patient-specific outcomes, and widen the range of treatable reproductive conditions. Induced pluripotent stem cells are adult somatic cells that have been genetically reprogrammed to an embryonic-like pluripotent state, enabling them to differentiate into nearly any cell type in the body. For example, in January 2025, Gameto Inc., a U.S.-based biotechnology company, launched a pivotal Phase III clinical trial for its iPSC-derived fertility therapy, Fertilo, following Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). The trial, which will take place across approximately 15 sites in the U.S., aims to assess egg maturation outside the body using engineered ovarian support cells, potentially shortening IVF cycles and reducing hormonal stimulation by up to 80%. If successful, this would be the first late-stage clinical program for in-vitro matured egg therapy derived from induced pluripotent stem cells in infertility treatment.
In October 2023, REPROCELL Inc., a biotechnology company based in Japan, acquired Gameto Inc. for an undisclosed amount. This acquisition aims to strengthen REPROCELL's position in the fertility and regenerative medicine sectors by integrating Gameto's advanced iPSC-based fertility technologies to accelerate the development of innovative infertility treatments. Gameto Inc. is a U.S.-based biotechnology company that specializes in stem cell therapy for infertility.
Major companies operating in the stem cell therapy for infertility market are PlacidWay LLC, New Life India Fertility Clinic Private Limited, Jeevan Mithra Fertility Centre Private Limited, Equipo IVI S.L., Hope Fertility & Stem Cell Centre Pvt. Ltd., Bioscience Institute SpA, Advancells Dermaceuticals Private Limited, GIOSTAR INDIA PRIVATE LIMITED, Shree IVF Clinic Private Limited, Stem Cells Care (india) Private Limited, GenCell Ltd., StemRx BioScience Solutions Private Limited., Kiran Infertility Centre Private Limited, R3 Stem Cell LLC., Bavishi Fertility Institute Private Limited, Seragen Biotherapeutics Private Limited, Esha IVF Fertility Centre Private Limited, Embryonic Tissue Center EmCell, InoCells B.V., Vega Stem Cell Clinic Co. Ltd.
North America was the largest region in the stem cell therapy for infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stem cell therapy for infertility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the stem cell therapy for infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The stem cell therapy for infertility market includes revenues earned by providing services such as fertility restoration therapy services, clinical research support services, biobanking of stem cell services, allogeneic stem cell transplantation services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Stem Cell Therapy For Infertility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on stem cell therapy for infertility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for stem cell therapy for infertility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stem cell therapy for infertility market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.